Osteoarthritis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Osteoarthritis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month5 studies across 1 company, in the next 180 days.
December 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ZBH | Zimmer Biomet | Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder SystemNCT01480440observationalSurvivorship | — | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-04-28 |
| ZBH | Zimmer Biomet | Comprehensive Reverse Shoulder Data CollectionNCT03404778observationalPain Score | — | Enrolling by invitation | Dec 2026 | ≤ 133 d | 2025-10-30 |
| ZBH | Zimmer Biomet | Database Retrieval for the Comprehensive ShoulderNCT03409718observationalImplant survivorship is assessed counting the number of implant revisions | — | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-07-10 |
| ZBH | Zimmer Biomet | Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating SystemNCT03626038Re-operation | Not applicable | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-02-13 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ZBH | Zimmer Biomet | PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip ArthroplastyNCT03372278observationalImplant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method | — | Active, not recruiting | Jan 2027 | ≤ 164 d | 2025-06-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Osteoarthritis
most recently updated first311 studies match. Showing the first 100 of 311 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $1.15T | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainNCT07641517Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | Phase 2 | Recruiting | Drug: LY4065967, Placebo | Osteoarthritis, Knee, Chronic Pain | 150 | 2026-06-25 | Apr 2027 | ≤ 253 d | 2026-08-19 |
| ZBH | Zimmer Biomet | $18.9B | Persona Ti-Nidium Post-Market Clinical Follow-upNCT04817969Oxford Knee Score (OKS) | Not applicable | Active, not recruiting | Device: Zimmer Biomet Persona Ti-Nidium Total Knee System | Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of the Knee, Avascular Necrosis, Patellofemoral Osteoarthritis | 240 | 2021-06-01 | May 2034 | ≤ 2,841 d | 2026-08-17 |
| NVO | Novo Nordisk A/S | — | AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Osteoarthritis, Knee | 400 | 2026-04-20 | 2028-08-14 | in 725 d | 2026-08-17 |
| SNN | Smith & Nephew, Inc. | — | A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory ArthritisNCT05197036observationalImplant Survivorship (femoral and/or tibial component) 2 Years Post-Surgery | — | Active, not recruiting | Procedure: Total Knee Arthroplasty | Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis | 299 | 2021-12-21 | 2026-06-11actual | — | 2026-08-11 |
| ZBH | Zimmer Biomet | $18.9B | A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral StemNCT02851992results2023-12-01Mean Harris Hip Score | Not applicable | Terminatedsponsor's stated reason: Zimmer Biomet is prioritizing specific products within its portfolio and has chosen not to extend the CE mark for the GTS stem under MDR requirements, leading to the premature termination of the GTS study in 2024. | Device: GTS cementless stem | Osteoarthritis, Hip | 303 | Sep 2012 | May 2020actual | — | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score | Phase 3 | Recruiting | Drug: Orforglipron, Placebo | Osteoarthritis | 800 | 2025-09-15 | Apr 2028 | ≤ 619 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931Percent Change from Baseline in Body Weight | Phase 3 | Recruiting | Drug: Eloralintide, Placebo | Osteoarthritis, Overweight or Obesity | 900 | 2026-02-09 | Mar 2028 | ≤ 589 d | 2026-08-06 |
| ZBH | Zimmer Biomet | $18.9B | G7 Acetabular System With Vivacit-E or Longevity Liner PMCF StudyNCT04754087Survival of the study device (liner); whether or not it is still implanted in the subject | Not applicable | Active, not recruiting | Device: Vivacit-E and Longevity (HXLPE) Liners | Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip | 300 | 2021-07-07 | 2033-12-31 | in 2,690 d | 2026-07-16 |
| ZBH | Zimmer Biomet | $18.9B | Database Retrieval for the Comprehensive ShoulderNCT03409718observationalImplant survivorship is assessed counting the number of implant revisions | — | Active, not recruiting | Device: Biomet Comprehensive Shoulder System | Osteoarthritis of the Shoulder, Avascular Necrosis, Rheumatoid Arthritis, Prior Failed Revision, Correction of Functional Deformity, Fracture of Proximal End of Humerus, Cuff Tear Arthropathy | 160 | 2011-02-24 | Dec 2026 | ≤ 133 d | 2026-07-10 |
| ZBH | Zimmer Biomet | $18.9B | Persona Revision Knee System OutcomesNCT04821154observationalKnee Society Clinical Rating System objective knee score (KS-KS) | — | Recruiting | Device: Persona Revision Knee System | Arthroplasty Complications, Infection, Knee Disease, Knee Osteoarthritis | 380 | 2021-06-14 | 2033-12-31 | in 2,690 d | 2026-07-10 |
| ZBH | Zimmer Biomet | $18.9B | Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)NCT05787821observationalOxford Knee Score (OKS) | — | Active, not recruiting | Device: Total Knee Arthroplasty | Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis | 760 | 2023-06-28 | 2026-06-30actual | — | 2026-07-10 |
| ZBH | Zimmer Biomet | $18.9B | Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder ArthroplastyNCT03726554Implant Survivorship | Not applicable | Active, not recruiting | Device: Comprehensive Reverse Porous Augmented Glenoid, Comprehensive Mini Humeral Tray | Arthropathy of Shoulder Region, Grossly Deficient Rotator Cuff, Osteoarthritis of the Shoulder, Rheumatoid Arthritis Without Humeral Metaphyseal Defects, Post-Traumatic Arthritis | 99 | 2018-08-28 | Feb 2030 | ≤ 1,288 d | 2026-07-09 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainNCT05986292Number of Participants Who Were Allocated to Each ISA | Phase 2 | Recruiting | Drug: LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 10,000 | 2020-01-30 | Apr 2027 | ≤ 253 d | 2026-06-23 |
| SNN | Smith & Nephew, Inc. | — | JOURNEY™ II CR Total Knee SystemNCT02440672observationalEquivalence in 1 year post-operative mean Range of Motion (ROM) in subjects receiving the J II CR TKS as compared to the literature reference mean ROM | — | Active, not recruiting | Device: JOURNEY™ II CR Total Knee System (J II CR TKS) | Osteoarthritis, Knee | 170 | Sep 2015 | Jun 2028 | ≤ 680 d | 2026-06-12 |
| ZBH | Zimmer Biomet | $18.9B | TESS V3 Modular Total Shoulder System PMCFNCT05002959observationalImplant survival at 10 years | — | Terminatedsponsor's stated reason: Termination of PMCF study due to product discontinuation (commercial reasons) | Device: Anatomic TESS V3, Reverse TESS V3 | Osteoarthritis Shoulder, Rheumatoid Arthritis, Rheumatoid Arthritis Shoulder, Avascular Necrosis, Revision, Rotator Cuff Tears, Osteonecrosis, Rotator Cuff Tear Arthropathy, Proximal Humeral Fracture, Malunion of Fracture, Shoulder Region | 67 | 2022-02-01 | 2026-03-05actual | — | 2026-06-09 |
| ZBH | Zimmer Biomet | $18.9B | Sidus(TM) Post Market Clinical Follow-up (PMCF) StudyNCT01700543observationalFunctional Performance (Constant & Murley Score) | — | Completed | Procedure: Shoulder Arthroplasty | Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Osteoarthritis, Inflammatory Joint Disease (IJD), Rheumatoid Arthritis | 152 | Oct 2012 | Jul 2020actual | — | 2026-06-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066Percent Change From Baseline in Body Weight | Phase 3 | Completed | Drug: Retatrutide, Placebo | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 2,335 | 2023-07-10 | 2026-04-06actual | — | 2026-06-03 |
| ZBH | Zimmer Biomet | $18.9B | Subchondroplasty® Knee RCTNCT03112200results2026-05-14Composite Clinical Success | Not applicable | Completed | Procedure: Subchondroplasty with Arthroscopy, Arthroscopy Alone | Bone Marrow Edema, Knee Pain Chronic, Knee Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis | 131 | 2017-03-29 | 2023-08-23actual | — | 2026-05-14 |
| ZBH | Zimmer Biomet | $18.9B | A Multicenter Prospective Randomized Control Study on Persona Total Knee System vs NexGenNCT03073941results2025-01-17Oxford Knee Score | Not applicable | Active, not recruiting | Device: Persona total knee system, Nexgen total knee system | Osteoarthritis, Knee | 332 | Dec 2016 | 2021-11-23actual | — | 2026-05-12 |
| ZBH | Zimmer Biomet | $18.9B | ROSA Total Knee Post Market Study EMEANCT04338893results2026-01-21Alignment Accuracy | Not applicable | Completed | Procedure: Device: Persona Total Knee, Device: NexGen Total Knee, Device: Vanguard Total Knee | Knee Pain, Chronic Osteoarthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus or Flexion Deformities, Rheumatoid Arthritis | 252 | 2020-12-15 | 2025-08-22actual | — | 2026-05-12 |
| ZBH | Zimmer Biomet | $18.9B | Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder SystemNCT01480440observationalSurvivorship | — | Active, not recruiting | Device: Trabecular Metal Reverse Shoulder System | Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Ununited Humeral Head Fracture, Irreducible 3-and 4-part Proximal Humeral Fractures, Avascular Necrosis, Gross Rotator Cuff Deficiency, Revision Total Shoulder Arthroplasty | 200 | Jan 2011 | Dec 2026 | ≤ 133 d | 2026-04-28 |
| ZBH | Zimmer Biomet | $18.9B | Zimmer Biomet Shoulder Arthroplasty PMCFNCT04984291Implant Survivorship at 10 years follow-up (Kaplan Meier) | Not applicable | Recruiting | Device: Alliance Glenoid, Identity Stem | Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity, Shoulder Injuries, Shoulder Pain | 584 | 2021-07-28 | 2033-08-15 | in 2,552 d | 2026-04-28 |
| ZBH | Zimmer Biomet | $18.9B | Cemented vs Cementless Persona Keel RCTNCT05630053Oxford Knee Score (OKS) | Not applicable | Active, not recruiting | Device: Cementless Persona Knee System, Cemented Persona Knee System | Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis, Polyarthritis, Avascular Necrosis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee | 300 | 2023-07-25 | May 2032 | ≤ 2,111 d | 2026-04-27 |
| ZBH | Zimmer Biomet | $18.9B | Persona Partial Knee Clinical Outcomes StudyNCT03034811Oxford Knee Score | Not applicable | Active, not recruiting | Device: Persona Partial Knee system | Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Conditional Tibial Condyle or Plateau Fractures, Conditional Revision of the Articular Surface | 757 | 2017-02-08 | Sep 2030 | ≤ 1,502 d | 2026-04-22 |
| ZBH | Zimmer Biomet | $18.9B | Comprehensive Nano - Post Market Clinical Follow-Up StudyNCT03423953observationalSurvivorship | — | Active, not recruiting | Device: Comprehensive Nano | Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Revision, Correction of Functional Deformity | 194 | 2013-10-30 | 2030-07-31 | in 1,441 d | 2026-04-21 |
| ORGO | Organogenesis | $230M | A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the KneeNCT06000410The difference in change from baseline in WOMAC Pain scale at 6 months between ASA- and placebo-treated patients | Phase 3 | Completed | Biological: Amniotic Suspension Allograft · Drug: Placebo | Knee Osteoarthritis | 594 | 2023-09-06 | 2025-08-15actual | — | 2026-04-21 |
| ZBH | Zimmer Biomet | $18.9B | A Prospective Multicenter Longitudinal Cohort Study of the Mymobility PlatformNCT03737149results2026-03-23Phase II (RCT): Readmissions | Not applicable | Completed | Other: mymobility with Apple Watch | Osteoarthritis, Knee, Osteoarthritis, Hip | 6,559 | 2018-10-22 | 2025-04-15actual | — | 2026-03-23 |
| SNN | Smith & Nephew, Inc. | — | OXINIUM◊ DH Total Hip Arthroplasty Pivotal StudyNCT02353377results2026-03-19Overall Success at 730 Days Post-operative in Participants With a Unilateral Hip Implant | — | Active, not recruiting | Device: OXINIUM DH Hip System, BIOLOX◊ | Hip Osteoarthritis | 413 | Jan 2015 | 2021-09-21actual | — | 2026-03-19 |
| SNN | Smith & Nephew, Inc. | — | TITAN™ Reverse Shoulder SystemNCT02204228observationalSurvival (lack of implant component removal or revision) | — | Terminatedsponsor's stated reason: Business reasons not related to safety | Device: TITAN™ Reverse Shoulder System (TRS) | Osteoarthritis of the Shoulder | 151 | Sep 2014 | 2023-12-14actual | — | 2026-03-13 |
| SNN | Smith & Nephew, Inc. | — | A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip SystemNCT06564636observationalCollared CATALYSTEM™ femoral stem implant survivorship 2 years post-operatively | — | Active, not recruiting | Device: CATALYSTEM | Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis, Avascular Necrosis, Post-traumatic Arthritis, Congenital Hip Dysplasia | 119 | 2024-09-26 | Dec 2027 | ≤ 498 d | 2026-03-12 |
| ZBH | Zimmer Biomet | $18.9B | Persona Total Knee Arthroplasty Outcomes StudyNCT02255383Knee Society Score | Not applicable | Active, not recruiting | Device: Zimmer Persona Total Knee System | Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Moderate Varus, Valgus or Flexion Deformities, Avascular Necrosis of the Femoral Condyle | 737 | Jul 2014 | Dec 2025actual | — | 2026-03-10 |
| ZBH | Zimmer Biomet | $18.9B | ROSA® Knee System V1.5 Pilot StudyNCT07009912Incidence of Procedure-Emergent Adverse Events, to assess the Safety of the ROSA® Knee System v1.5 System | Not applicable | Completed | Device: Total Knee Arthroplasty | Knee Arthroplasty, Total, Robotic Surgical Procedures, Joint Diseases, Knee Osteoarthritis | 40 | 2025-02-25 | 2026-02-17actual | — | 2026-02-27 |
| ZBH | Zimmer Biomet | $18.9B | Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating SystemNCT03626038Re-operation | Not applicable | Active, not recruiting | Device: A.L.P.S. Proximal Humerus Plating System | Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture | 135 | 2018-06-19 | Dec 2026 | ≤ 133 d | 2026-02-13 |
| ZBH | Zimmer Biomet | $18.9B | Allofit® IT With HXPE in Total Hip ArthroplastyNCT03672929results2026-01-27observationalSurvival of the Implant System | — | Completed | — | Avascular Necrosis, Osteoarthritis, Hip, Inflammatory Arthritis, Post-Traumatic Osteoarthritis of Hip | 197 | 2011-06-05 | 2025-07-03actual | — | 2026-01-27 |
| SNN | Smith & Nephew, Inc. | — | POLARSTEM Cementless Hip StemNCT02648152results2026-01-21observationalKaplan-Meier Estimate: Overall Survivorship of POLARSTEM | — | Completed | Device: Total Hip Arthroplasty | Osteoarthritis | 218 | Mar 2009 | Nov 2020actual | — | 2026-01-21 |
| SNY | Sanofi | — | A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the KneeNCT06704932Number of participants with adverse events (AEs)/treatment emergent adverse events (TEAEs) including injection site reactions | Phase 1 | Completed | Drug: SAR446959, Placebo | Osteoarthritis | 32 | 2024-11-20 | 2025-12-18actual | — | 2026-01-12 |
| ZBH | Zimmer Biomet | $18.9B | Randomized Controlled Clinical Evaluation to Compare Vanguard Cruciate Retaining and AGC Total Condylar Knee ImplantsNCT01064063American Knee Society Knee Score | Not applicable | Completed | Device: Vanguard CR, AGC knee | Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis | 150 | 2011-02-15 | 2013-12-15actual | — | 2025-11-26 |
| ZBH | Zimmer Biomet | $18.9B | A Prospective, Clinical Investigation of the Vanguard 360 Revision KneeNCT01542580observationalAMERICAN KNEE SOCIETY KNEE SCORE | — | Active, not recruiting | Device: Vanguard SSK 360 with PS Bearing, Vanguard SSK 360 with PSC bearing, Vanguard DA 360, Vanguard 360 TiNbN Femur with PS bearing, Vanguard 360 TiNbN Femur with PSC bearing | Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity, Complications; Arthroplasty, Deformity of Limb | 255 | Mar 2012 | Dec 2031 | ≤ 1,959 d | 2025-11-25 |
| ZBH | Zimmer Biomet | $18.9B | Avenir® Cemented Hip Stem - PMCFNCT03396224observationalImplant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method | — | Active, not recruiting | — | Primary Osteoarthritis, Post-Traumatic Osteoarthritis of Hip, Femoral Neck Fractures, Femoral Head Necrosis, Sequelae From Previous Hip Surgery, Osteotomies, Congenital Hip Dysplasia | 100 | 2015-11-18 | Nov 2030 | ≤ 1,563 d | 2025-11-25 |
| ZBH | Zimmer Biomet | $18.9B | BC Study of G7 Cup and Compatible Femoral StemsNCT03456622observationalSurvival of the implant system | — | Active, not recruiting | — | Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis | 230 | Nov 2015 | Jun 2029 | ≤ 1,045 d | 2025-11-25 |
| ZBH | Zimmer Biomet | $18.9B | Z1 Hip System: Post-Market Clinical Follow Up StudyNCT07104279observational2 Year Survivorship | — | Recruiting | Device: Z1 Femoral Hip System | Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head | 150 | 2025-10-13 | Aug 2028 | ≤ 742 d | 2025-11-10 |
| ZBH | Zimmer Biomet | $18.9B | Comprehensive Reverse Shoulder Data CollectionNCT03404778observationalPain Score | — | Enrolling by invitation | Device: Biomet Comprehensive Reverse Shoulder | Arthropathy of Shoulder Region, Grossly Deficient Rotator Cuff, Osteoarthritis of the Shoulder, Rheumatoid Arthritis Without Humeral Metaphyseal Defects, Post-Traumatic Arthitis | 175 | 2010-03-07 | Dec 2026 | ≤ 133 d | 2025-10-30 |
| MMSI | Merit Medical Systems, Inc. | $5.3B | GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)NCT05818150Primary Efficacy Endpoint | Not applicable | Active, not recruiting | Device: Embosphere Microspheres · Drug: Corticosteroid injection | Knee Osteoarthritis | 264 | 2024-01-16 | Apr 2026 | — | 2025-10-24 |
| ZBH | Zimmer Biomet | $18.9B | G7 Freedom Constrained Vivacit-E LinersNCT05587244Survival of the study device | Not applicable | Enrolling by invitation | Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners | Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures, Femoral Neck Fractures, Avascular Necrosis, Dislocation, Hip | 202 | 2023-05-08 | Dec 2037 | ≤ 4,151 d | 2025-10-20 |
| ORGO | Organogenesis | $230M | Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the KneeNCT04636229The difference in change from baseline in WOMAC Pain scale at 6 months between ASA- and placebo-treated patients | Phase 3 | Completed | Biological: Amniotic Suspension Allograft · Drug: Placebo | Knee Osteoarthritis | 516 | 2020-12-14 | 2023-07-30actual | — | 2025-10-16 |
| ZBH | Zimmer Biomet | $18.9B | Safety and Efficacy of the Oxford Cementless Partial Knee SystemNCT01473134results2024-09-19Radiographic Success | Not applicable | Completed | Device: Oxford Cementless Partial Knee, Oxford Cemented Partial Knee | Osteoarthritis, Knee, Avascular Necrosis of the Medial Femoral Condyle | 320 | Dec 2011 | 2020-11-30actual | — | 2025-08-11 |
| ZBH | Zimmer Biomet | $18.9B | G7 BiSpherical Acetabular Shell PMCF StudyNCT03266874observationalImplant survivorship is assessed counting the number of implant revisions | — | Active, not recruiting | — | Rheumatoid Arthritis, Osteoarthritis, Noninflammatory Degenerative Joint Disease, Avascular Necrosis, Correction of Functional Deformity, Non-Union Fracture, Femoral Neck Fractures, Trochanteric Fractures | 160 | 2017-12-10 | Dec 2029 | ≤ 1,229 d | 2025-06-25 |
| ZBH | Zimmer Biomet | $18.9B | Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) StudyNCT01307384observationalSurvivorship | — | Active, not recruiting | Device: Continuum Metal on Polyethylene Acetabular System | Avascular Necrosis, Osteoarthritis, Inflammatory Arthritis, Post-traumatic Arthritis, Rheumatoid Arthritis | 165 | 2011-03-29 | Dec 2027 | ≤ 498 d | 2025-06-18 |
| ZBH | Zimmer Biomet | $18.9B | Exception Cementless Hip StemNCT04349046observationalImplant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method | — | Active, not recruiting | Device: Total hip arthoplasty (THA) | Osteoarthritis, Hip, Rheumatoid Arthritis, Inflammatory Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of Hip, Femoral Neck Fractures | 332 | 2021-01-01 | 2024-05-01actual | — | 2025-06-18 |
| ZBH | Zimmer Biomet | $18.9B | Avenir Complete Post-Market Clinical Follow-Up StudyNCT04731077Survival of the study device; whether or not it is still implanted in the subject | Not applicable | Active, not recruiting | Device: Avenir Complete Femoral Stem | Osteoarthritis, Hip, Avascular Necrosis of Hip, Avascular Necrosis of the Femoral Head, Post-traumatic; Arthrosis | 275 | 2021-09-27 | 2035-06-01 | in 3,207 d | 2025-06-18 |
| ZBH | Zimmer Biomet | $18.9B | PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip ArthroplastyNCT03372278observationalImplant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method | — | Active, not recruiting | — | Rheumatoid Arthritis With Adequate Bone Quality, Inflammatory Arthritis, Osteoarthritis, Hip, Avascular Necrosis, Post-traumatic; Arthrosis, Congenital Hip Dysplasia | 250 | Jan 2013 | Jan 2027 | ≤ 164 d | 2025-06-15 |
| ZBH | Zimmer Biomet | $18.9B | G7 Dual Mobility With Vivacit-E or Longevity PMCFNCT05548972Survival of the implant system | Not applicable | Enrolling by invitation | Device: G7 Dual Mobility with Vivacit-E bearing, G7 Dual Mobility Longevity bearing | Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis, Dislocation, Hip, Femoral Neck Fractures, Trochanteric Fractures, Revision Surgeries | 358 | 2023-03-20 | Jan 2037 | ≤ 3,817 d | 2025-06-15 |
| ZBH | Zimmer Biomet | $18.9B | ArCom® and ArComXL® Polyethylene Data CollectionNCT00565786observationalPolyethylene wear rates | — | Completed | Device: ArCom® Polyethylene, ArComXL® Polyethylene | Osteoarthritis of Hip | 150 | Jul 2004 | 2017-01-17actual | — | 2025-06-11 |
| ZBH | Zimmer Biomet | $18.9B | Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient PopulationNCT02087449observationalHHS score | — | Terminatedsponsor's stated reason: Sponsor decided to terminate study. | Device: E1-Hip Bearing | Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Rheumatoid Arthritis, Legg-perthes Disease | 100 | Feb 2013 | Dec 2017actual | — | 2025-04-02 |
| SNN | Smith & Nephew, Inc. | — | Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in Unicondylar Knee Arthroplasty (UKA) ProceduresNCT04797897results2025-03-25Post-operative Leg Alignment | Not applicable | Terminatedsponsor's stated reason: The Study terminated prematurely due to very low patient enrollment in the study. | Device: CORI, Conventional | Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Requires Correction of Functional Deformity, Fracture, Knee | 4 | 2022-02-12 | 2023-09-29actual | — | 2025-03-25 |
| ZBH | Zimmer Biomet | $18.9B | Allofit® IT Ceramic Bearing System in Total Hip ArthroplastyNCT03672916results2025-02-12observationalSurvivorship | — | Completed | — | Avascular Necrosis of Hip, Osteoarthritis, Hip, Inflammatory Arthritis, Post-Traumatic Osteoarthritis of Hip | 185 | May 2011 | Apr 2023actual | — | 2025-02-12 |
| AZN | AstraZeneca | — | A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the KneeNCT04675034results2025-02-10Change From Baseline in Weekly Average of Daily Numerical Rating Scale (NRS) Pain Score to Week 12 | Phase 2 | Completed | Drug: MEDI7352 · Other: Placebo | Painful Osteoarthritis of the Knee | 345 | 2020-12-02 | 2023-08-16actual | — | 2025-02-10 |
| ZBH | Zimmer Biomet | $18.9B | DenCT Shoulder Bone Quality EvaluationNCT06032416CT scan data acquisition | Not applicable | Not yet recruiting | Radiation: Preoperative CT Scan | Osteoarthritis Shoulder, Rotator Cuff Tears | 200 | Apr 2025 | Apr 2026 | — | 2025-02-10 |
| ZBH | Zimmer Biomet | $18.9B | Prospective Clinical Follow-up of the Echo Bi-Metric Microplasty Stem for Total Hip ArthroplastyNCT04326010observationalImplant Survival | — | Terminatedsponsor's stated reason: Data collected up to this point has provided sufficient follow-up and will allow for a reasonable estimate of the five-year survivorship rate for the Echo Bi-Metric Microplasty stem in primary total hip arthroplasty. | Device: Surgery | Hip Osteoarthritis | 206 | 2017-02-20 | 2024-06-14actual | — | 2025-02-05 |
| ZBH | Zimmer Biomet | $18.9B | ROSA® Hip System THA PMCFNCT05497206Accuracy of implant position | Not applicable | Terminatedsponsor's stated reason: The data needed for regulatory submissions based on the current pace of the study, will not be available in the foreseeable future. | Device: One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System | Osteoarthritis, Hip, Avascular Necrosis of Hip | 12 | 2024-06-05 | 2024-12-12actual | — | 2025-02-05 |
| ZBH | Zimmer Biomet | $18.9B | Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up StudyNCT03343171observationalSafety will be evaluated by adverse events reporting. | — | Active, not recruiting | — | Osteoarthritis, Avascular Necrosis, Inflammatory Arthritis, Post-traumatic Arthritis | 203 | 2010-09-15 | Feb 2025 | — | 2025-01-31 |
| ZBH | Zimmer Biomet | $18.9B | Vanguard™ Deep Dish Rotating Platform Knee Clinical EvaluationNCT00753090results2025-01-30Knee Society Score | Not applicable | Completed | Device: Vanguard™ Deep Dish Rotating Platform Knee, Vanguard™ Cruciate Retaining Knee | Osteoarthritis | 326 | Jun 2009 | 2022-07-15actual | — | 2025-01-30 |
| ANIK | Anika Therapeutics, Inc. | $289M | MONOVISC for Hip Joint Pain Relief Due to OsteoarthritisNCT04204083results2025-01-28Numerical Rating Scale (NRS) Pain on Walking | Not applicable | Completed | Device: Monovisc | Osteoarthritis, Hip | 25 | 2019-12-17 | 2021-02-26actual | — | 2025-01-28 |
| ZBH | Zimmer Biomet | $18.9B | Arcos Revision Stem: Evaluation of Clinical PerformanceNCT01820611results2025-01-20observationalSurvivorship | — | Completed | Device: Arcos Revision Stem System | Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Deformity, Fracture, Complications; Arthroplasty | 74 | Feb 2013 | 2021-06-14actual | — | 2025-01-20 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the KneeNCT05008835results2025-01-09Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Intensity Scores | Phase 2 | Terminatedsponsor's stated reason: Study was terminated for business reasons. | Drug: ACP-044 Dose A, ACP-044 Dose B, Placebo | Osteoarthritis Pain | 61 | 2021-07-20 | 2022-10-06actual | — | 2025-01-09 |
| ZBH | Zimmer Biomet | $18.9B | Continuum™ Metal Bearing System in Total Hip ArthroplastyNCT03382652results2024-12-16observationalImplant Survival at 10 Years | — | Completed | Device: Metal-on-Metal Articulation | Avascular Necrosis, Osteoarthritis, Inflammatory Arthritis, Post-traumatic; Arthrosis, Total Hip Arthroplasty | 83 | 2011-02-09 | 2022-10-22actual | — | 2025-01-03 |
| ZBH | Zimmer Biomet | $18.9B | Vivacit-E Post-market Follow-up StudyNCT03226808Survival of the study device; whether or not it is still implanted in the subject | Not applicable | Active, not recruiting | Device: Vivacit-E Liner | Osteoarthritis, Avascular Necrosis of Bone of Hip, Post-traumatic; Arthrosis, Congenital Hip Dysplasia | 258 | 2013-10-01 | 2026-03-02 | — | 2025-01-01 |
| ZBH | Zimmer Biomet | $18.9B | NexGen TM Tibia Clinical Outcomes StudyNCT03272373results2024-12-05Radiograph Assessment of Progressive Tibial Radiolucencies | Not applicable | Completed | Device: NexGen TM Monoblock Tibia, NexGen TM Modular Tibia | Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities | 160 | 2017-10-03 | 2023-03-30actual | — | 2024-12-30 |
| ZBH | Zimmer Biomet | $18.9B | MDR - Longevity IT Oblique and Offset LinersNCT05980234observationalIncidence of treatment-emergent Adverse Events (safety) | — | Terminatedsponsor's stated reason: Zimmer Biomet received the CE mark for the Continuum and Trilogy IT Acetabular System, which includes the Longevity IT Offset and Oblique Liners, in June 2024. | Device: Total Hip Arthroplasty with Longevity IT Oblique Liners, Total Hip Arthroplasty with Longevity IT Offset Liners | Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Protrusio Acetabuli, Traumatic Arthritis, Slipped Capital Femoral Epiphyses, Fracture of the Pelvis, Diastrophic Variant, Osteoarthritis, Fused Hip | 6 | 2023-08-30 | 2024-11-02actual | — | 2024-12-27 |
| AMGN | Amgen | $229.9B | Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug TreatmentNCT00984815results2013-07-25Number of Participants With Treatment Emergent Adverse Events | Phase 3 | Completed | Drug: HZT-501 | Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain | 86 | Sep 2009 | Jul 2011actual | — | 2024-12-18 |
| ZBH | Zimmer Biomet | $18.9B | The Metaphyseal Hip Prosthesis - Total HipNCT01501955results2018-08-13RSA Translation X | Not applicable | Completed | Device: Metaphyseal Hip Prosthesis, Stanmore | Osteoarthritis of the Hip | 20 | Oct 2012 | Jan 2016actual | — | 2024-12-18 |
| AMGN | Amgen | $229.9B | Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)NCT00613106results2011-06-17Number of Participants With Treatment Emergent Adverse Events | Phase 3 | Completed | Drug: HZT-501, Ibuprofen | Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain | 179 | Sep 2007 | Oct 2008actual | — | 2024-12-17 |
| ANIK | Anika Therapeutics, Inc. | $289M | Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip JointNCT04640298results2024-03-07Numerical Rating Scale (NRS) Pain on Walking | Not applicable | Completed | Device: Cingal | Osteoarthritis, Hip | 25 | 2021-01-16 | 2021-09-10actual | — | 2024-12-16 |
| ZBH | Zimmer Biomet | $18.9B | Metasul Monoblock Component™ Cup in a Hip Resurfacing Application With the Durom® Hip Resurfacing Femoral ComponentNCT03681639results2024-12-03Implant Survival | Not applicable | Completed | Diagnostic test: Serum Metal ion levels determined to monitor changes in chromium and cobalt levels | Avascular Necrosis of Hip, Osteoarthritis, Hip, Rheumatoid Arthritis, Inflammatory Arthritis, Post-traumatic; Arthrosis | 45 | 2009-08-01 | 2023-05-22actual | — | 2024-12-03 |
| ZBH | Zimmer Biomet | $18.9B | AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical StudyNCT03357445Survivorship | Not applicable | Active, not recruiting | Other: Avantage Reload cup | Primary Osteoarthritis, Post-Traumatic Arthritis, Inflammatory Joint Disease, Femoral Neck Fracture, Femoral Head Necrosis, Sequelae From Previous Hip Surgery, Osteotomies, Congenital Hip Dysplasia | 500 | 2011-10-14 | 2027-04-27 | in 250 d | 2024-11-14 |
| ZBH | Zimmer Biomet | $18.9B | Fitmore Hip Stem PMCF Study: A Multi-centre, Non-comparative, Prospective Post-market Clinical Follow-up Study.NCT03411044results2024-10-17observationalHarris Hip Score | — | Completed | Device: Fitmore Hip Stem | Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Prosthesis Failure | 420 | 2008-02-08 | 2023-06-10actual | — | 2024-11-05 |
| ZBH | Zimmer Biomet | $18.9B | A Study Comparing Ceramic-on-metal Articulation to Metal-on-metal Articulation in Cementless Primary Hip ArthroplastyNCT00754520results2024-10-02Composite Clinical Success (CCS) Rate as Defined in the Protocol | Not applicable | Completed | Device: Ceramic On Metal, Metal on Metal | Osteoarthritis | 213 | May 2009 | Dec 2021actual | — | 2024-10-02 |
| ZBH | Zimmer Biomet | $18.9B | A Clinical Investigation of the Vanguard™ Complete Knee SystemNCT00698854observationalKSS | — | Completed | Device: Vanguard™ Complete Knee System, Vanguard™ Patient-Specific Femur | Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Lower Limb Deformity, Complications, Arthroplasty | 552 | Mar 2004 | Jan 2021actual | — | 2024-09-19 |
| ZBH | Zimmer Biomet | $18.9B | nSTRIDE APS Versus Hyaluronic Acid for Knee OsteoarthritisNCT03182374results2024-09-19Change From Baseline to 12 Months Post-injection in Mean WOMAC LK3.1 Pain Score in Both Arms of the Study (nSTRIDE APS and Synvisc One) | Not applicable | Completed | Device: nSTRIDE APS, Synvisc-One | Osteoarthritis, Knee | 252 | 2017-07-14 | 2019-09-30actual | — | 2024-09-19 |
| OGN | Organon and Co | $3.6B | Survey of Osteoarthritis Real World Therapies (MK-0663-140)NCT01294696results2014-03-04observationalPercentage of Participants Who Reported Adequate vs. Inadequate Pain Relief at Baseline | — | Completed | Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Osteoarthritis | 1,261 | Oct 2010 | Jan 2013actual | — | 2024-08-29 |
| ZBH | Zimmer Biomet | $18.9B | Prospective Multi-centre Outcomes Study of Persona Knee System in Total Knee ArthroplastyNCT04461626observationalImplant Survivorship | — | Completed | Device: Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system) | Knee Osteoarthritis | 1,017 | 2014-11-19 | 2023-06-30actual | — | 2024-08-22 |
| ZBH | Zimmer Biomet | $18.9B | Investigation to Determine Safety of Taperloc Stems With BioGuard Coating When Used in Cementless Total Hip ArthroplastyNCT02263209Change in normalised peri-implant BMD as measured by DXA | Not applicable | Active, not recruiting | Device: Bioguard Group, Control Group | Osteoarthritis of Hip | 50 | Oct 2013 | Nov 2015actual | — | 2024-08-16 |
| OGN | Organon and Co | $3.6B | Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)NCT00092703Discontinuations due to clinical and laboratory gastrointestinal adverse experiences during a 1 year treatment period. | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: Diclofenac sodium | Osteoarthritis | 6,000 | 2002-06-27 | 2003-11-01actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | An Investigational Drug in Patients With Osteoarthritis (0663-073)NCT00092755WOMAC VA 3.0 pain subscale, WOMAC VA 3.0 physical function subscale, and Patient Global Assessment of Disease Status Scale. Efficacy data collected at Weeks 2, 4, 8, and 12. | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparators: ibuprofen and placebo | Osteoarthritis | 548 | 2003-04-09 | 2003-11-13actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)NCT00092768Osteoarthritis of the knee & hip as assessed by WOMAC VA 3.0 pain and physical function subscales, Patient/Investigator assessments of disease and response to therapy over 12 weeks of treatment. | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: celecoxib | Osteoarthritis | 500 | 2004-03-01 | 2005-02-01actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)NCT00092781Osteoarthritis of the knee & hip as assessed by WOMAC VA 3.0 pain and physical function subscales, Patient/Investigator assessments of disease and response to therapy over 12 weeks of treatment. | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: celecoxib | Osteoarthritis | 500 | 2004-03-01 | 2005-02-01actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)NCT00140972WOMAC pain subscale | Phase 4 | Completed | Drug: MK0663; etoricoxib / Duration of Treatment:4 Weeks, Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks | Osteoarthritis | 160 | 2004-12-03 | 2005-06-27actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)NCT00269191Pain and physical function over 12-weeks as assessed by the WOMAC VA 3.0 pain subscale, WOMAC VA 3.0 physical function subscale, and Patient Global Assessment of Disease Status, as well as safety over 12-weeks as assessed by adverse experiences. | Phase 3 | Completed | Drug: MK0663, etoricoxib / Duration of Treatment 12 Weeks, Placebo or Ibuprofen / Duration of Treatment 12 Weeks | Osteoarthritis | 528 | 2003-02-05 | 2003-11-07actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)NCT00542087This study will assess the effectiveness of the study drug vs. a comparator to treat successfully OA-related joint pain (judged by WOMAC pain subscale). | Phase 3 | Completed | Drug: MK0663, etoricoxib / Duration of Treatment: 6 Weeks, Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks | Osteoarthritis | 516 | 2002-03-22 | 2002-12-20actual | — | 2024-08-15 |
| SNN | Smith & Nephew, Inc. | — | JOURNEY II XR Safety and Effectiveness PMCFNCT03136887observationalImplant survival rate | — | Active, not recruiting | Device: JOURNEY II XR Total Knee System | Rheumatoid Vasculitis With Rheumatoid Arthritis of Knee, Unilateral Post-Traumatic Osteoarthritis of Knee, Knee Osteoarthritis, Degenerative Arthritis Peripheral Joint, Failed Osteotomies, Failed Unicompartmental Replacement | 176 | 2017-07-28 | Apr 2029 | ≤ 984 d | 2024-08-12 |
| ZBH | Zimmer Biomet | $18.9B | Exceed ABT Acetabular Cup Cementless SystemNCT04255394results2024-07-26observationalHarris Hip Score | — | Completed | — | Osteoarthritis, Rheumatoid Arthritis, Correction of Functional Deformity | 677 | 2010-07-01 | 2022-02-28actual | — | 2024-07-26 |
| ZBH | Zimmer Biomet | $18.9B | Persona TM Tibia Clinical Outcomes StudyNCT03589300results2024-07-23Radiograph Assessment of Progressive Tibial Radiolucencies | Not applicable | Completed | Device: Persona TM Tibia | Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities | 148 | 2018-04-30 | 2022-11-30actual | — | 2024-07-23 |
| LLY | Eli Lilly and Company | $1.15T | Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With OsteoarthritisNCT05080660results2023-09-06Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | Phase 2 | Completed | Drug: LY3526318, Placebo | Osteoarthritis, Osteo Arthritis Knee | 160 | 2021-10-12 | 2022-06-06actual | — | 2024-07-17 |
| OGN | Organon and Co | $3.6B | The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)NCT01980940results2015-12-11Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing | Phase 1/2 | Completed | Drug: Etoricoxib 75 mg 4% DMSO Gel, Etoricoxib 75 mg 4% PG Gel, Etoricoxib 150 mg 4% DMSO Gel, Etoricoxib 150 mg 4% PG Gel, Etoricoxib 163 mg 4% DMSO gel, Placebo, Etoricoxib 50 mg 4% DMSO, Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel | Osteoarthritis Pain | 70 | 2013-12-23 | 2014-11-26actual | — | 2024-06-27 |
| LLY | Eli Lilly and Company | $1.15T | A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis PainNCT05620563results2024-06-26Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | Phase 2 | Completed | Drug: LY3857210, Placebo | Osteoarthritis | 147 | 2022-11-22 | 2023-06-05actual | — | 2024-06-26 |
| BVS | Bioventus LLC | $985M | Study of StimRouter for Chronic Knee OA PainNCT05644639observationalKnee Pain | — | Completed | Device: StimRouter Neuromodulation System | Osteoarthritis, Knee | 13 | 2022-10-18 | 2023-10-01actual | — | 2024-06-26 |
| EPRX | Eupraxia Pharmaceuticals Inc. | $244M | Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the KneeNCT04120402results2024-06-25Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale | Phase 2 | Completed | Drug: EP-104IAR 25 mg, Vehicle | Osteoarthritis, Knee | 318 | 2021-09-10 | 2023-05-17actual | — | 2024-06-25 |
| SNN | Smith & Nephew, Inc. | — | Safety and Efficacy of the Journey II BCS Total Knee SystemNCT01705067observationalRate of ITB Friction Pain | — | Completed | Device: TKA with Journey II BCS Total Knee System | Osteoarthritis, Knee | 209 | Jun 2012 | 2023-07-31actual | — | 2024-06-13 |
| ZBH | Zimmer Biomet | $18.9B | Oxford UKA and HTO Post-market Clinical StudyNCT04518111observationalOxford Knee Score | — | Unknown status | — | Knee Osteoarthritis | 370 | 2021-04-24 | 2024-09-30 | — | 2024-05-23 |
| ZBH | Zimmer Biomet | $18.9B | Clinical Evaluation of Vanguard DD RPNCT04076202Performance | Not applicable | Active, not recruiting | Device: Cementless Vanguard DD RP | Knee Osteoarthritis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis | 113 | 2013-07-11 | 2018-08-26actual | — | 2024-05-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Osteoarthritis is matched — 18 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Osteoarthritis
- Osteoarthritis, Knee
- Osteoarthritis, Hip
- Knee Osteoarthritis
- Osteoarthritis of the Knee
- Hip Osteoarthritis
- Osteoarthritis of the Shoulder
- Osteoarthritis Knee Pain
- Post-Traumatic Osteoarthritis of Hip
- Chronic Osteoarthritis
- Osteoarthritis Pain
- Osteoarthritis Shoulder
- Osteoarthritis of Hip
- Osteoarthritis of the Hip
- Painful Osteoarthritis of the Knee
- Patellofemoral Osteoarthritis
- Primary Osteoarthritis
- Shoulder Osteoarthritis
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Osteoarthritis” (a text search, wider than this page)